The DOI matches its Crossref record.
Preferential action of gabapentin and pregabalin at P/Q‐type voltage‐sensitive calcium channels: Inhibition of K+‐evoked [3H]‐norepinephrine release from rat neocortical slices
Abstract
Gabapentin (GBP; Neurontin®) and pregabalin (PGB; CI‐1008), efficacious drugs in several neurological and psychiatric disorders, inhibit neurotransmitter release from mammalian brain slices at therapeutically relevant concentrations. A detailed investigation, exploring the basis for this in vitro phenomenon, focused on norepinephrine (NE) and rat neocortical tissue in complementary assays of neurotransmitter release and radioligand binding. The results are consistent with the hypothesis that GBP, PGB, and related substances decrease neocortical NE release by acting at the α 2 δ subunit of presynaptic P/Q‐type voltage‐sensitive Ca 2+ channels (VSCC) subserving Ca 2+ influx in noradrenergic terminals. The inhibitory action appears competitive with [Ca 2+]o and preferential to those neurons undergoing prolonged depolarization. Other results indicate that the reduction of exocytotic NE release is independent of L‐ and N‐type VSCC, classical drug/peptide binding sites on VSCC, Na+ channels, α 2‐adrenoceptors, NE transporter, and system L amino acid transporter. These findings suggest a selective modulation of P/Q‐type VSCC that are implicated in neurotransmission and several GBP‐responsive pathologies. Synapse 45:171–190, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Catterall, W. A., Goldin, A. L., & Waxman, S. G. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.4 · Cited by 2,254
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1430 · Cited by 1,239
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
The mechanisms of action of gabapentin and pregabalin
SILLS, G. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.003 · Cited by 671
Freynhagen, R., Strojek, K., Griesing, T., Whalen, E., & Balkenohl, M. (2005) · Pain · doi:10.1016/j.pain.2005.02.032 · Cited by 572
Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial
Lesser, H., Sharma, U., LaMoreaux, L., & Poole, R. M. (2004) · Neurology · doi:10.1212/01.wnl.0000145767.36287.a1 · Cited by 570
Taylor, C. P., Angelotti, T., & Fauman, E. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.09.008 · Cited by 565
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Ca2+ channel α2δ ligands: novel modulators of neurotransmission
Dooley, D. J., Taylor, C. P., Donevan, S., & Feltner, D. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.12.006 · Cited by 387
Self-citationProgress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.07.010 · Cited by 300
Cellular and behavioral interactions of gabapentin with alcohol dependence
Roberto, M., Gilpin, N. W., O'Dell, L. E., Cruz, M. T., Morse, A. C., Siggins, G. R., & Koob, G. F. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-08.2008 · Cited by 126
Dosing Time-Dependent Changes in the Analgesic Effect of Pregabalin on Diabetic Neuropathy in Mice
Akamine, T., Koyanagi, S., Kusunose, N., Hashimoto, H., Taniguchi, M., Matsunaga, N., & Ohdo, S. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.223891 · Cited by 33
Metadata
- Authors
- Dooley, D. J., Donovan, C. M., Meder, W. P., & Whetzel, S. Z.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2002-06-24
- Volume
- 45
- Issue
- 3
- Pages
- 171-190
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W2170481173
- Cited by
- 180
- References
- 0
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.